Premium
Effect of vasoactive peptides on prostacyclin synthesis in man
Author(s) -
Barrow Susan E.,
Dollery Colin T.,
Heavey Dennis J.,
Hickling Nicola E.,
Ritter James M.,
Vial Janet
Publication year - 1986
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1986.tb10177.x
Subject(s) - vasoactive , prostacyclin , vasoactive intestinal peptide , bradykinin , pharmacology , chemistry , endocrinology , medicine , neuropeptide , receptor
1 Bradykinin, angiotensin II, arginine vasopressin (AVP) or des‐amino‐D‐arginine vasopressin (DDAVP) were administered by intravenous infusion to 10 healthy men. 2 The concentration of 6‐oxo‐prostaglandin F 1α (6‐oxo‐PGF 1α ), the stable hydrolysis product of prostacyclin (PGI 2 ), was measured in plasma using gas chromatography/negative ion chemical ionisation mass spectrometry. 3 Dose‐related increases in plasma concentrations of 6‐oxo‐PGF 1α occurred during administration of bradykinin (100–3200 ng kg −1 min −1 ). The concentrations of 6‐oxo‐PGF 1α rose from baseline values in the range < 1.0–4.9 pg ml −1 to 24.9–47.6 pg ml −1 at maximum tolerated infusion rates. 4 There were no changes in the concentrations of 6‐oxo‐PGF 1α during administration of angiotensin II, AVP or DDAVP at infusion rates which caused haemodynamic changes.